Biomoda, Inc.
Teams with India’s Leading Diagnostic Testing Provider
World Leader in Laboratory Services and
Technology to aid Biomoda
Albuquerque, N.M. – (Business Wire),
Validation studies for Biomoda’s patented and patent
pending products for the early detection and targeted treatment of specific
cancers will be supported by the services of Metropolis Health Services, the largest
independent pathology laboratory system in India, a nation of more than 900
million.
“This represents a critical step as we accelerate
development”, said Company President,
“It offers a great pride to
Metropolis for having a mutual understanding with one of the leading
biopharmaceutical company’s like Biomoda, Inc. for providing clinical sample
services for their internal validation program” said Amit
Bhatt, Head-Clinical Trials. "The mission of Metropolis India,
will be to assist Biomoda Inc .in its innovative diagnostic research
services."
Metropolis Health Services (India) Pvt., Ltd., is a
Corporate chain of Diagnostic centers all over India. An ISO, CAP (College
of American Pathologists) and NABL (National Accreditation Board for
Laboratory Testing and Calibration Laboratories - ISO/IEC 17025:1999) accredited institution; Metropolis has many
“firsts” to its credit. As a company with 8 state of the art
laboratories, catering to the needs of more than 3000 small laboratories,
nursing homes, hospitals and over 10,000 consultants,
and processing more than 5 million samples per year, Metropolis has established
itself as a renowned Referral Laboratory Center in India.
In its 25 years of existence Metropolis has grown into one of the leading players in Asia and has diversified its service lines to include Clinical Research and Clinical Trial Management Services, Hospital Laboratory Management Services, Referral Pathology & Imaging Services and Preventive Health Services Metropolis is the only Indian Diagnostic chain to go international with a presence in the UAE and offices in the UK and US. The company is currently exploring opportunities in South East Asia, Sri Lanka, Middle East and Europe.
Biomoda, Inc., a development stage in-vitro diagnostics organization, is focused on research, development and commercialization of cancer diagnostics. The Company has several patents developed for noninvasive early detection and treatment of specific cancers is in the process of registering additional patents in this area. The Company’s proprietary technologies provide minimally invasive and minimal impact approaches as cancer diagnostic products. Biomoda's laboratory operations are situated at Kirtland Air Force Base (Albuquerque, NM).
*
* * * *
This news release contains forward-looking
statements that involve a high degree of risk and uncertainty. Such statements include, but are not limited
to, statements containing the words “believes,” “anticipates,” “expects,” “estimates,” and words of similar
import. The Company’s actual results
could differ materially from any forward-looking statements, which reflect
management’s opinions only as of the date of this report, as a result of risks
and uncertainties that exist in our operation, development efforts and business
environment. The Company undertakes no
obligation to revise or publicly release the results of any revisions to these
forward-looking statements. You should
carefully review the risk factors in other documents that the Company files
from time to time with the Securities and Exchange Commission, including its
Quarterly Reports on Form 10-Q. For
additional information, visit the Biomoda web site at www.biomoda.com or call
us at 505-821-0875.